CTNNA1 Genetic Study for Cancer Risk

CTNNA1 Familial Expansion Study

Recruiting Observational Study
Cancer Gene Mutation Gastric Cancer Breast Cancer
No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
100 (estimated)
Sponsor
Abramson Cancer Center at Penn Medicine · Other
Who this trial is looking for

This trial is looking for adults who are carriers of a specific genetic variant or have a close family member who is. Participants will help researchers understand cancer risks linked to a gene called CTNNA1.

Are You a Good Fit for This Trial?

You may be able to join if

  • I am 18 years of age or older
  • I carry a CTNNA1 loss-of-function variant or have a first degree relative who does
  • I can read and understand English
  • I can give my consent to participate

You may not be able to join if

  • I am under 18 years of age
  • I do not carry a CTNNA1 loss-of-function variant and have no first degree relative who does
  • I cannot read and understand English
  • I have major psychiatric illness or cognitive impairment that affects my ability to participate
  • I cannot comply with study procedures

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

The goal of the CAFÉ Study is to determine the cancer risks associated with germline CTNNA1 loss-of-function variants.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * 18 years of age and older * Participants must be carrier, or a first degree relative of a carrier, of a CTNNA1 loss-of-function variant defined as: a variant predicted to lead to protein truncation (nonsense and frameshift variants), a large deletion of one or more exons, or a…
Contacts

Bryson W Katona, MD, PhD

215-349-8222

cafestudy@pennmedicine.upenn.edu

CONTACT

Dana Farengo Clark, MS, LCGC

cafestudy@pennmedicine.upenn.edu

CONTACT